Welcome to our dedicated page for Nano-X Imaging news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging stock.
NANO-X IMAGING LTD reports news on an integrated medical imaging and healthcare services platform built around Nanox.ARC multisource digital tomosynthesis systems, AI and software solutions, cloud-based workflow tools, remote radiology access, health information technology and a marketplace model. Company updates commonly cover U.S. commercialization, distribution agreements, clinical collaborations and regulatory clearances tied to Nanox.ARC and related imaging capabilities.
Recurring financial and operating news also includes results from teleradiology services, imaging products and services, AI and software activity, and the completed addition of Nanox Health IT. The company frames its commercial activity around broader access to 3D imaging and preventive-care workflows across clinical settings.
Nanox (NASDAQ: NNOX) announced a U.S. distribution agreement with Integrity Medical Service to sell, implement and service the Nanox.ARC system across Colorado, Wyoming and western Kansas and Nebraska.
The agreement targets deployment of 4 systems in Year 1 and 12 systems in Year 2, and leverages Integrity’s field service engineers to support outpatient imaging adoption.
Nano-X Imaging (NASDAQ: NNOX) announced a U.S. distribution agreement with Elite Surgical Technologies to deploy the Nanox.ARC multisource digital tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia.
According to the company, the agreement targets orthopedic and post-surgical imaging, with a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption.
Nanox (NASDAQ: NNOX) announced on March 3, 2026 that Nanox Impact signed a distribution agreement with Imperial Imaging Technology to deploy the Nanox.ARC multisource digital tomosynthesis system across Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida.
Imperial will handle marketing, demos, clinical evaluations, installations, and customer support for orthopedic and musculoskeletal practices. According to the company, Nanox.ARC DTS imaging is reimbursable under an existing CPT code and requires no pre-authorization.
Nanox (Nasdaq: NNOX) announced an exclusive distribution agreement with Intec SRL for the Nanox.ARC digital tomosynthesis system in Argentina, dated Feb 19, 2026. Intec will manage marketing, distribution, installation, clinical evaluations, training and local support.
Commercial sales in Argentina are subject to required regulatory approvals; Intec will provide technical support and post-warranty service.
Nanox (Nasdaq: NNOX) will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI capabilities at ECR 2026 (March 4-8, Vienna).
The company will demonstrate TAP2D image enhancement, present ADOPT study data, and highlight FDA-cleared and CE-marked AI solutions for cardiac, bone and liver analysis.
Nanox (NNOX) announced FDA 510(k) clearance on February 3, 2026 for TAP2D, a cloud-enabled image enhancement for Nanox.ARC and Nanox.ARC X tomosynthesis systems. The feature generates a clear 2D view from a single tomosynthesis scan without additional radiation and integrates into existing workflows.
The clearance advances Nanox's regulatory pathway toward removing adjunct use in the US and enables remote software upgrades to existing installations as part of the company's rollout of imaging improvements.
Nanox (Nasdaq: NNOX) announced an exclusive distribution agreement with Adriamed to commercialize the Nanox.ARC digital tomosynthesis system in Serbia, Montenegro, and Bosnia and Herzegovina on January 14, 2026.
The Nanox.ARC holds a CE Mark for its intended use and Adriamed will handle marketing, distribution, installation, and support across the Western Balkans. The collaboration follows recent European agreements in Greece, Romania, Czech Republic, and France and aims to expand access to lower-cost 3D imaging for regional healthcare providers.
Nanox (Nasdaq: NNOX) announced a distribution collaboration with Althea France to introduce the CE-marked Nanox.ARC multi-source digital tomosynthesis system across France.
Althea France, part of the Althea Group that manages thousands of imaging devices, will lead market introduction, sales and service and leverage relationships with university hospitals, public hospitals and private clinics. This deal is Nanox's fourth European distribution agreement following partnerships in Greece, Romania and the Czech Republic. The Nanox.ARC is cleared for commercialization across the European Union following CE Mark certification.
Nanox (Nasdaq: NNOX) announced that its deep‑learning subsidiary Nanox.AI had two bone‑analysis tools — HealthVCF and the upgraded HealthOST — recommended by NICE for inclusion in an Early Value Assessment in UK NHS hospitals for a three‑year evidence‑generation period beginning November 24, 2025.
The tools will be assessed for their ability to support opportunistic detection of vertebral fragility fractures on X‑rays and CT scans, be compared with current NHS standard of care, and are eligible for core NHS funding while evidence is gathered. Two of five AI bone solutions in the assessment are from Nanox.AI.
Nanox (Nasdaq: NNOX) announced a registered direct offering of 3,826,530 ordinary shares expected to raise gross proceeds of approximately $15 million before offering expenses. The closing is expected on or about November 25, 2025, subject to customary closing conditions. The company said it intends to use net proceeds for working capital and general corporate purposes. Titan Partners Group is acting as sole placement agent. The offering is made under an effective Form F-3 shelf registration that became effective May 5, 2023, and will be described in a prospectus supplement filed with the SEC.